Marksans Pharma to Acquire 100% Stake in Netherlands-Based QliniQ B.V., Boosting European Market Reach

Marksans Pharma to Acquire 100% Stake in Netherlands-Based QliniQ B.V., Boosting European Market Reach​

Mumbai, June 1, 2026: Marksans Pharma Ltd, a leading pharmaceutical company, announced on June 1, 2026, that it has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V. QliniQ B.V. is a profitable, Netherlands-based pharmaceutical company with established front-end sales, marketing, and distribution capabilities across the Dutch healthcare market.

This acquisition marks a significant strategic move for Marksans Pharma, aiming to expand its presence across regulated European markets. The move is intended to strengthen the company's forward-integration strategy by providing direct, owned market-access capabilities within the European Union.

Strategic Value and Market Presence​

QliniQ operates a differentiated portfolio of niche pharmaceuticals and medical devices, with established positions in women's health, dermatology, respiratory care, and other specialty categories. The company benefits from long-standing relationships with wholesalers, pharmacies, hospitals, and insurer-led tender channels in the Netherlands, which supports sustainable market access and growth.

Mark Saldanha, Chairman and Managing Director of Marksans Pharma, stated that the acquisition is an important strategic step in expanding the company's reach in regulated European markets. He noted that the acquisition provides Marksans with direct access to the Netherlands market and enhances the capability to commercialize existing and future products across the broader European market.

The deal grants Marksans several critical advantages:

• Established sales, marketing, and distribution infrastructure in the Netherlands.
• Access to strong relationships with major wholesalers, pharmacies, hospitals, and health insurers.
• Participation in insurer-led tender channels with visibility across multiple product categories.
• EU GDP-compliant warehousing, wholesale distribution, and regulatory infrastructure.
• Multiple commercial routes through wholesalers, pharmacies, and direct-to-consumer channels.

QliniQ’s Financial Performance​

QliniQ B.V. is headquartered in Oldenzaal, Netherlands, and is engaged in the distribution and commercialization of niche prescription medicines and medical devices. Its portfolio includes areas such as women's health (contraceptives and menopause), dermatology, respiratory/ENT, endocrinology, and gastroenterology.

The company reported strong profitability and consistent growth. For the financial year ended 31 December 2025, QliniQ generated revenue of €9.35 million and reported a net profit of €1.01 million. Furthermore, the company recorded a Compound Annual Growth Rate (CAGR) of approximately 41% in revenue between FY2023 and FY2025, all while maintaining a debt-free balance sheet.

The financials for QliniQ B.V. for the year ended 31 December are detailed below:

Future Outlook​

Albert de Bruin and Raymond Lansink, Board members and Shareholders of QliniQ B.V., expressed optimism regarding the partnership. They stated that combining QliniQ's market presence and local expertise with Marksans' strong track record in product development and manufacturing expertise creates a compelling opportunity for future growth and value creation.

The total consideration for the acquisition of 100% shareholding in QliniQ B.V. is set at € 7,500,000. The acquisition is expected to be completed by 15 June 2026 or any other date agreed upon by the parties in writing.

MARKSANS Stock Price Movement​

Shares of MARKSANS PHARMA LIMITED are edging higher to ₹248.8 as of the 9:05 AM pre-open session, gaining 1.06% in early trading. The movement suggests strong pre-market momentum for the pharmaceutical stock heading into the official market open.